France · Delayed Price · Currency is EUR ABIVAX Société Anonyme Earnings Call Transcripts
Fiscal Year 2026
-
ABTECT Maintenance Part 2 results show obefazimod delivers robust, durable efficacy and a favorable long-term safety profile in highly refractory ulcerative colitis patients. Exposure-adjusted safety events remain within expected ranges, supporting regulatory confidence and broad clinical use.
-
The phase III ABTECT maintenance trial in ulcerative colitis showed both 25 mg and 50 mg obefazimod achieved best-in-class clinical and endoscopic remission rates with a favorable safety profile over 44 weeks, outperforming current therapies and supporting dose flexibility for future use.
Fiscal Year 2025
-
Phase III data showed significant efficacy and safety for an oral therapy in moderate to severe UC, including highly refractory and JAK inhibitor-failure patients. Clinicians anticipate broad use due to dosing flexibility, favorable safety, and potential for early-line adoption.
-
Phase 3 induction trials for obefazimod in ulcerative colitis showed significant efficacy and a favorable safety profile, with both 25 mg and 50 mg doses meeting key endpoints and the 50 mg dose demonstrating robust remission rates. Maintenance data are expected in Q2 2026.
-
The meeting reviewed strong clinical progress, robust board changes, and a challenging financial year, with future growth hinging on upcoming phase III results for obefazimod. All resolutions, including governance and capital measures, were approved.